Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
E Fox, SE Bates - Expert review of anticancer therapy, 2007 - Taylor & Francis
P-glycoprotein actively transports structurally unrelated compounds out of cells, conferring
the multidrug resistance phenotype in cancer. Tariquidar is a potent, specific …
the multidrug resistance phenotype in cancer. Tariquidar is a potent, specific …
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
M Yu, A Ocana, IF Tannock - Cancer and Metastasis Reviews, 2013 - Springer
Enhanced drug extrusion from cells due to the overexpression of the ATP-binding cassette
(ABC) drug transporters inhibits the cytotoxic effects of structurally diverse and …
(ABC) drug transporters inhibits the cytotoxic effects of structurally diverse and …
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group
T Büchner, WE Berdel, C Haferlach… - Journal of Clinical …, 2009 - ascopubs.org
Purpose The purpose of the study was to assess the contribution of age and disease
variables to the outcome of untreated patients with acute myeloid leukemia (AML) receiving …
variables to the outcome of untreated patients with acute myeloid leukemia (AML) receiving …
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized …
LD Cripe, H Uno, EM Paietta, MR Litzow… - Blood, The Journal …, 2010 - ashpublications.org
Zosuquidar, which modulates P-glycoprotein (P-gp) with minimal delay of anthracycline
clearance, may reverse P-gp–mediated resistance in acute myeloid leukemia without …
clearance, may reverse P-gp–mediated resistance in acute myeloid leukemia without …
Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs
EK Baker, RW Johnstone, JR Zalcberg, A El-Osta - Oncogene, 2005 - nature.com
The mechanism of action of chemotherapeutic drugs and their ability to induce multidrug
resistance (MDR) are of relevance to cancer treatment. Overexpression of P-glycoprotein …
resistance (MDR) are of relevance to cancer treatment. Overexpression of P-glycoprotein …
MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia
M Schaich, S Soucek, C Thiede… - British journal of …, 2005 - Wiley Online Library
Multi drug resistance (MDR) is a major obstacle for cancer therapy. The three major
candidates accounting for the development of MDR in acute myeloid leukaemia (AML) are …
candidates accounting for the development of MDR in acute myeloid leukaemia (AML) are …
Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)
MM Van den Heuvel-Eibrink, EAC Wiemer, A Prins… - Leukemia, 2002 - nature.com
Expression of the multidrug resistance proteins P-glycoprotein, encoded by the MDR1 gene,
multidrug resistance-associated protein (MRP1) and the lung resistance-related protein or …
multidrug resistance-associated protein (MRP1) and the lung resistance-related protein or …
Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers
Numerous molecular markers have been recently discovered as potential prognostic factors
in acute myeloid leukemia (AML). It has become of critical importance to thoroughly evaluate …
in acute myeloid leukemia (AML). It has become of critical importance to thoroughly evaluate …
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute …
JE Kolitz, SL George, RK Dodge, DD Hurd… - Journal of Clinical …, 2004 - ascopubs.org
Purpose P-glycoprotein (Pgp) is strongly inhibited by PSC-833. A chemotherapy dose-
escalation study was performed with PSC-833 in patients younger than 60 years with …
escalation study was performed with PSC-833 in patients younger than 60 years with …
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the …
AK Burnett, D Milligan, A Goldstone… - British journal of …, 2009 - Wiley Online Library
The acute myeloid leukaemia (AML) 14 trial addressed four therapeutic questions in patients
predominantly aged over 60 years with AML and High Risk Myelodysplastic Syndrome:(i) …
predominantly aged over 60 years with AML and High Risk Myelodysplastic Syndrome:(i) …